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This study determined the efficacy and safety of a modified FOLFOX regimen that improved patient convenience without
compromising oxaliplatin dose intensity. A total of 62 patients with previously untreated metastatic colorectal cancer were enrolled
to receive, entirely as outpatients, 2-weekly cycles of oxaliplatin 100mgm
 2 i.v. over 2h, together with leucovorin 400mgm
 2 over
2h, 5-fluorouracil (5-FU) 400mgm
 2, bolus, followed by a 46-h infusion of 5-FU at 2.4gm
 2. Treatment was given until progression
or unmanageable toxicity. In all, 61 patients received Xone oxaliplatin dose and a median of 11 treatment cycles (range 1–20 cycles);
22 (36%) reported grade 3/4 neutropenia and 13 patients (21%) experienced grade 3 neurotoxicity; 16 patients (26%) discontinued
treatment due to disease progression or death, 15 (25%) due to neurotoxicity and six (10%) due to haematological toxicity. Of the
56 eligible patients, complete or partial responses were observed in 29 or 52% (95% confidence interval 38–65%). Median
progression-free survival was 8.2 months (7.1–9.9) and median overall survival was 18.7 months (14.0–23.4). In our experience, a
modified schedule of FOLFOX improves convenience without compromising efficacy or toxicity.
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Oxaliplatin unlike cisplatin has demonstrated activity against
colon carcinoma cell lines in vitro and has also shown synergistic
activity in experimental models (Raymond et al, 1997). Several
large randomised trials have confirmed the efficacy of the
oxaliplatin/5-fluorouracil (5-FU)/leucovorin (LV) combination as
first-line therapy in metastatic colorectal cancer. In De Gramont’s
et al (2000) phase III trial, FOLFOX4 was significantly superior to
the infusional regimen, LV5FU2, in response rate and progression-
free survival (PFS) and the combination of chronomodulated
5-FU/LV and oxaliplatin produced a significantly higher response
rate and superior PFS to the 5-FU/LV regimen alone (Giacchetti
et al, 2000). In a recent three-arm study in 796 untreated patients
with metastatic colorectal cancer (Goldberg et al, 2004), FOLFOX4
was significantly superior to the irinotecan and bolus 5-FU/LV
combination (IFL) and a third regimen of oxaliplatin plus
irinotecan (IROX) in response rate, time to progression and
overall survival, and induced fewer Grade 3 or 4 toxicities.
The original FOLFOX4 regimen, however, does have drawbacks
for patients, as it requires intravenous treatment in hospital for
48-h every 2 weeks. Several variations of this regimen, incorporating
oxaliplatin dose intensification or simplification of the LV/5-FU
schedule, have been evaluated in clinical trials.
A retrospective analysis by Maindrault-Goebel et al (2000) of
three phase II studies, in previously treated patients, using three
different FOLFOX regimens showed that increased oxaliplatin dose
intensity (485mgm
 2) improved response rates and PFS without
compromising tolerability. One of the more effective regimens,
FOLFOX6, utilised an oxaliplatin dose of 100mgm
 2 on day 1 in
combination with a simplified bimonthly 5-FU/LV schedule (LV
400mgm
 2 on day 1 only, followed by 5-FU bolus 400mgm
 2,
then 2400–3000mgm
 2 as a 46-h infusion). In the phase II trial
with FOLFOX6 in pretreated patients, a response rate of 27% was
achieved, but with significant grade 3 or 4 neutropenia (24%) and
neurotoxicity of 16% (Maindrault-Goebel et al, 1999).
In this Australian phase II study in untreated patients with
metastatic colorectal cancer, we also sought to simplify the
treatment delivery schedule of the active FOLFOX4 regimen
without compromising dose intensity. We eliminated the 2nd
day bolus dose of 5-FU, increased the dose of oxaliplatin to
100mgm
 2 and increased the 5-FU infusion to 46h, similar to
FOLFOX6, and also utilised disposable pumps to allow an entirely
outpatient treatment. In the algorithm for dose reductions due to
haematological toxicity, we chose, in contrast to FOLFOX6, to
preferentially dose-reduce 5-FU rather than oxaliplatin, aiming to
maximise oxaliplatin dose intensity. In FOLFOX6 both the
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soxaliplatin dose was reduced to 75mgm
 2 and 5-FU infusion to
2000mgm
 2 without altering the bolus dose of 5-FU. In our
schema the first dose adjustment was elimination of the bolus
5-FU, the second was reduction of the continuous infusion of 5FU
and only then reduction of oxaliplatin. The primary objective of
our study was to determine the objective response rate of this
modified FOLFOX6 regimen. Our secondary objective was to
assess the qualitative and quantitative toxicities of this regimen.
PATIENTS AND METHODS
Patients
Patients with a histologically confirmed diagnosis of advanced
adenocarcinoma of the colon or rectum were eligible to be entered
into the trial provided they were aged X18 years, had measurable
disease (defined as at least one lesion with at least one diameter
X2cm), ECOG performance status (PS) of 0–2 and had completed
adjuvant treatment 6 or more months prior to study entry. Patients
who received prior adjuvant treatment with oxaliplatin were not
eligible. To be included, patients also had to have a serum
creatinine p160mmoll
 1, bilirubin p1.5  the upper limit of
normal (ULN), ALT p4 ULN, an absolute neutrophil count
(ANC) X1.5 10
9l
 1, platelets X100 10
9l
 1 and peripheral
neuropathy pNCI Common Toxicity Criteria (CTC) grade 1.
Patients were required to provide signed informed consent.
Patients were excluded if they had received prior therapy for
advanced colorectal cancer, any uncontrolled infection, a history
of myocardial infarction within the previous 6 months or current
clinical evidence of congestive heart failure or unstable angina, a
history of any other cancer (except nonmelanoma skin cancer or
carcinoma in situ of the cervix) unless in complete remission and
off all therapy for that cancer for at least 5 years, central nervous
system metastases, or were pregnant or lactating or could not
provide informed consent. Men and women of reproductive
potential had to agree to use effective contraception.
Study design
The study protocol was approved by each of the participating
institutions’ ethics committees and was conducted according to the
Declaration of Helsinki. This was an open-label multicentre trial to
assess the response rate and quantitative and qualitative toxicities
of a modified schedule of FOLFOX.
Patients were registered by the investigator faxing the registra-
tion form to the sponsor SanofiBSynthelabo and then treatment
could commence.
Chemotherapy
Treatment was given entirely as an outpatient. On day 1 of each
2-week cycle, patients received oxaliplatin (Eloxatin
s supplied by
SanofiBSynthelabo) 100mgm
 2 given as an intravenous infusion
over 2h together with LV 400mgm
 2 over 2h and then 5-FU
400mgm
 2 as a bolus injection followed by a 46-h continuous
infusion of 5-FU at a total dose of 2.4gm
 2 (Figure 1). Cycles were
repeated at 2-week intervals until disease progression or unac-
ceptable toxicity developed. Treatment with a 5HT3 receptor
antagonist was recommended to control nausea and vomiting. All
treatments were administered via implantable ports and using
disposable pumps (Baxter Corporation).
Dose modification
Toxicities were graded according to the NCI CTC version 2.0, 30
January 98, except for oxaliplatin-induced neurosensory toxicity,
for which a specific grading scale was used. This scale was a
combination of the NCI CTC and the Levi et al scale (Levi et al,
1992).
Doses of oxaliplatin and 5-FU were modified in a stepwise
fashion according to a specific algorithm in the case of febrile
neutropenia, ANC o0.5 10
9l
 1, platelet nadir o50 10
9l
 1 or a
1–3-week dose delay due to prolonged ANC, or platelet, recovery.
Initially, the bolus dose of 5-FU was omitted from subsequent
cycles; then, if the toxicity recurred, the 5-FU infusional dose was
reduced to 2gm
 2 for subsequent cycles, and then the oxaliplatin
dosage was reduced to 75mgm
 2 for subsequent cycles. Since 5-
FU has previously been shown to contribute more to neutropaenia
and since the bolus dose was the most convenient component to
modify it was chosen first, followed by the infusional component.
This strategy was subsequently also chosen by the French group in
designing the Folfox7 regimen (Maindrault-Goebel et al, 2001).
Treatment could be recommenced once febrile neutropenia
resolved or the ANC improved to X1.5 10
9l
 1 or the platelet
count improved to X100 10
9l
 1. If the toxicities recurred after
the described 5-FU and oxaliplatin dose modifications, or a dose
was delayed 42 weeks due to toxicity, study therapy was
discontinued. No dose reductions were planned for changes in
haemaglobin or total white blood cell concentrations.
Neurological symptoms were assessed according to a specific
Neurosensory Toxicity Scale, which rated neurological symptoms
Grade 1–4 according to their persistence, degree of functional
impairment and impact on activities of daily living (ADL). Grade 1
described neurological symptoms that resolved and did not
interfere with function, grade 2 symptoms interfered with function
but not ADL, grade 3 toxicity indicated pain or functional
impairment that interfered with ADL and grade 4 denoted
persistent symptoms that were disabling or life threatening.
If patients experienced grade 2 or 3 neurosensory toxicity,
oxaliplatin and 5-FU were both withheld until symptoms resolved
and then restarted at a reduced dose of 75mgm
 2. If symptoms
recurred, oxaliplatin was again withheld until resolution and then
restarted at a reduced dose of 50mgm
 2. If symptoms recurred
after two dose reductions, or persisted after a dose delay of 42
weeks, treatment was discontinued due to unacceptable neuro-
sensory toxicity. Failure of neurotoxicity to return to grade I
necessitated removal from the study. If pseudo-laryngopharyngeal
dysesthesiae occurred, subsequent doses of oxaliplatin were
administered as a 6-h infusion.
Study parameters
Assessments for haematological parameters and biochemistry were
performed every 2 weeks prior to each cycle and patients were
questioned for symptoms of neurosensory toxicity prior to each
oxaliplatin dose.
All tumours were measured by the same imaging method used at
baseline for tumour size. A measurable tumour was defined as a
mass with clearly defined margins and could be clearly measured
on physical exam, X-ray or other radiograph with a ruler or
caliper. At least one diameter had to be X2cm on radiographic
imaging. Lesions with all dimensions o1cm were omitted.
5-FU bolus 400 mg m−2
D1 
LV 
400 mg m−2
5-FU infusion via disposable pump 
2.4 g m−2 over 46 h
Oxaliplatin 
100 mg m−2
0 h  2 h            48 h
Figure 1 Chemotherapy regimen.
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sResponses were assessed every four cycles (8 weeks). Complete
and partial responses were confirmed by repeat tumour evalua-
tions at least 4 weeks later. Standard definitions and standard
criteria for bidimensional measurement were used according to
WHO (Miller et al, 1981) in assessing responses. Stable disease
(SD) was confirmed after 4 weeks and had to last a minimum of 16
weeks from the commencement of therapy.
Progression-free survival was measured from the date of
commencing protocol treatment to the date of first progression
or death from any cause without progression. Overall survival was
measured from the date of commencing protocol treatment to the
date of death from any cause.
Statistical considerations
Confidence intervals (CO) (95%) for the response rates were
estimated using the exact probabilities of the binomial distribu-
tion.
The Kaplan–Meier method was used to calculate PFS and OS.
Statistical analyses were performed using StatXact procedures.
(StatXact 4.0.1. Cytel Software Corporation, Cambridge, MA, USA,
1999).
Dose intensity was defined as the actual dose intensity relative to
the protocol dose intensity. The initial doses of the drugs used
were calculated using BSA in m2¼exp (0.425 ln(weight)þ
0.725 ln(height) 4.9358) to assess whether initial doses were
given as per protocol. The relative dose intensities were calculated
for each drug by dividing the total dose given as a proportion of
the planned protocol dose by the total number of days on
treatment relative to protocol time. The protocol time was 14 days
for each cycle given. The total number of days on treatment was
calculated from day 1 of the first cycle to 14 days after day 1 of the
last cycle.
RESULTS
Patient characteristics
A total of 62 patients were registered from four Australian centres
between September 1999 and October 2000. In all, 61 patients
received Xone dose of oxaliplatin and were analysed for treatment
and safety results. Pretreatment characteristics of these patients are
listed in Table 1. While the median age was 61 years (range 31–
76), 59% were aged 60 years or older, 21% were over 70, 97% were
Caucasian.
Six of the 62 registered patients were deemed ineligible; one who
had received adjuvant treatment less than 6 months prior to study
entry, two with insufficient measurable disease, one who had
received prior radiosensitising chemotherapy for advanced disease
and two with laboratory parameters outside the eligible range on
the days of treatment. The remaining 56 eligible patients were
analysed for efficacy.
At the close-out date of 22 May 2003, the median potential
follow-up time from the commencement of treatment was 37
months (range 31–44 months).
Treatment given
In total, 587 cycles were given, with a range of 1–20 cycles and a
median of 11 2-weekly cycles per patient.
Out of 61 patients, 58 received more than one cycle of therapy.
Of these, 46 (79%) experienced a dose reduction of more than 10%
relative to the dose in cycle 1 for at least one drug. In all, 26
patients (45%) had their oxaliplatin dose reduced and one patient
(2%) had their leucovorin dose reduced by 410% on at least one
cycle as an unspecified administrative error. A total of 44 patients
(76%) had their 5-FU bolus dose and 27 (47%) had their 5-FU
infusion dose reduced by 410% on at least one cycle.
Although the protocol specified 14 days between cycles, only
eight patients (14%) received all their treatment cycles within 72
days of the protocol 14-day period. In total, 136 cycles (23%) in 50
patients were delayed more than 2 days. Of these, 116 cycles (20%)
were delayed for toxicity reasons.
Objective tumour responses
Of the 56 eligible patients, the best response to treatment was
assessed as a complete response (CR) in three patients (5%) and a
partial response (PR) in 26 patients (46%), for an overall objective
response rate of 52% (95% CI 38–65%). The full response data are
shown in Table 2.
Progression-free survival (PFS)
By the close-out date, four patients (7%) were alive without
progression (two have since died) and 52 patients (93%) had
progressed (two patients died without objective evaluation of their
progression). The estimated median PFS was 8.2 months (95% CI
7.1–9.9 months) with an estimated proportion of patients
surviving without progression of 30% (95% CI 20–44%) at 1 year
and 11% (5–22%) at 2 years (Figure 2).
Survival
As at the close-out date, 10 (18%) patients were still alive and 46
(82%) patients had died, 45 (80%) due to progressive disease and
Table 1 Patient characteristics at registration (total 61 patients who
received X1 oxaliplatin dose)
No. %
Sex 45 74
Male 16 26
Female
ECOG performance status
02 9 4 8
12 4 3 9
28 1 3
Primary site
Colon 40 66
Rectum 21 34
Prior adjuvant therapy for colorectal cancer
No 41 67
Yes 20 33
Table 2 Best objective response to treatment
Total (56)
No. %
Complete response (CR) 3 5
Partial response (PR) 26 46
Stable disease (SD) 10 18
Progressive disease (PD) 9 (12)
a 16 (21%)
a
Not assessable (NA)
b 8 (5)
a 14 (9%)
a
aThree patients were not assessable by our criteria, but displayed clinical disease
progression that was not objectively validated (two received only two treatment
cycles before clinical progression and one received four cycles and only one
assessment before clinical progression).
bNot assessable patients were one patient
who had clinical disease progression after two cycles but was too unwell to repeat
imaging, five patients who received fewer than planned cycles of therapy, one patient
whose scans were lost and was thus not assessed properly at cycle 7, and one patient
who received only one assessment before clinical progression.
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sone (2%) during surgery for complications of colorectal cancer.
The estimated median OS was 18.7 months (95% CI 14.0–23.4
months), with an estimated proportion of patients surviving of
73% (95% CI 60–83%) at 1 year and 34% (23–47%) at 2 years
(Figure 3).
Dose intensity
The median relative dose intensity of oxaliplatin was 83%, range
39–103%, of LV 88%, range 39–102%, of bolus 5-FU 50%,
range 0–102% (omitted for haematologic or gastrointestinal
toxicity) and of 5-FU infusion 83%, range 35–103%. In all, 55%
of patients received 100þ/5% of oxaliplatin for all cycles given –
see Figure 4.
Toxicity
At the study close-out date, of the 61 patients who received Xone
treatment cycle, two patients (3%) had completed 12 treatment
cycles and 59 patients (97%) had discontinued treatment. In all, 16
patients (26%) discontinued due to disease progression or death,
25 (41%) due to toxicity (15 (25%) neurotoxicity, 6 (10%)
haematological toxicity and four (7%) due to other toxicity), 14
(23%) due to a decision of the patient or investigator and four
(7%) due to other reasons.
Grade 2, 3 and 4 acute toxicities are listed in Tables 3 and 4. The
most commonly reported toxicity was neutropenia. Grade 3/4
neutropenia occurred in 22 (36%) patients; however, only three
patients (5%) experienced febrile neutropenia. There were no toxic
deaths.
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Figure 2 Progression-free survival. Ticks indicate censored survival times.
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Table 3 Haematological toxicities (Worst grade while on treatment)
Total¼61
Grade 2 –
No. (%)
Grade 3 –
No. (%)
Grade 4 –
No. (%)
Thrombocytopenia 9 (15) 4 (7) 0 (0)
Neutropenia 18 (30) 17 (28) 5 (8)
Febrile neutropenia 3 (5)
Table 4 Nonhaematological toxicities
Total¼61
Grade 2 – No. (%) Grade 3 – No. (%) Grade 4 – No. (%)
Diarrhoea 12 (20) 7 (11) 0 (0)
Mucositis 7 (11) 2 (3) 0 (0)
Vomiting 7 (11) 2 (3) 0 (0)
Neurological 20 (33) 13 (21) 0 (0)
Fatigue 3 (5) 2 (3) 0 (0)
Nausea 6 (10) 2 (3) 0 (0)
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experiencing grade 2 and 13 patients (21%) experiencing grade 3
neurotoxicity during or post treatment. No grade 4 neurotoxicity
was reported.
For patients with grade 2/3 neurotoxicity, the median time to
recovery to grade 0/1 after ceasing treatment was estimated via the
Kaplan–Meier method to be 3.9 months (95% CI 0–6.7 months). It
was also estimated that 36% (21–54%) and 21% (10–40%) had
persisting grade 2 or 3 neurotoxicity at 6 and 12 months,
respectively. For grade 3 neurotoxicity specifically, it was
estimated that 71% of the patients had recovered 12 months after
ceasing treatment.
Two patients experienced a worsening of their neurological
toxicity from grade 1 to 2 and one patient reported grade 3
myopathy after ceasing treatment.
Hospitalisations during treatment
Nine patients (15%) required hospitalisation for toxicity; two
patients for febrile neutropenia, one patient with fever and rigours
without neutropenia, two patients with nausea and vomiting
(including one patient with additional abdominal pain), one with
diarrhoea (grade 3) and dehydration (grade 2), one for investiga-
tion of chest pain, one with porta-cath site erythema to investigate
infection, and one with candidiasis and elevated blood sugar.
A total of 19 (31%) of patients were hospitalised for other
reasons, not related to toxicity.
DISCUSSION
The combination of oxaliplatin and 5-FU/LV has proven to be a
major advance in the treatment of colorectal cancer both in the
metastatic and now adjuvant setting (Andre ´ et al, 2004). Studies
with successive FOLFOX regimens are attempting to define the
optimal oxaliplatin/5-FU/LV dose schedule. Important considera-
tions include the haematological toxicity, a recognised side effect
of both oxaliplatin and 5-FU treatment, and the cumulative
neurotoxicity, which is dictated by oxaliplatin treatment duration.
In our study, we used a modified FOLFOX6 regimen, which
focused upon maximising oxaliplatin dose intensity and improved
patient convenience by allowing all patients to be treated as
outpatients and reducing the number of outpatient visits. The
response rate of 52% and the median PFS and OS of 8.2 and 18.7
months, respectively, is at the upper end of those reported in
randomised trials of FOLFOX4 as front-line therapy, and similar to
that of FOLFOX6 (Tournigand et al, 2004) in previously untreated
metastatic colorectal cancer.
This is the first report of this modification to the FOLFOX6
regimen in untreated patients and the only report of this simplified
FOLFOX regimen in either pretreated or untreated patients outside
Europe. As such, it confirms a modification that is more
convenient than FOLFOX4 and appears to have at least compar-
able, if not enhanced, efficacy, due to the increased oxaliplatin
dose. In addition, there was neither a major increase in
neurotoxicity or haematological toxicity compared to FOLFOX4
in the metastatic setting.
One of the two issues identified in the analysis of phase II
studies of different FOLFOX combinations was the hypothesis that
the dose intensity of oxaliplatin is important. Early studies with
folfox 2 at 100mgm
 2 showed a high response rate (46%) but high
neurotoxicity. Subsequently, reduction in oxaliplatin dose to
85mgm
 2 in Folfox4, lowered toxicity but compromised efficacy
(24%), with a dose intensity of oxaliplatin of 74mgm
 2. (reviewed
in Maindrault-Goebel et al, 2000). Thus, in FOLFOX6, the dose of
oxaliplatin was increased from 85 to 100mgm
 2. However, in the
phase II trials with this regimen, dose intensity remained reduced
compared to Folfox2, where 89% of patients had 485mgm
 2 vs
only 59% for Folfox6. In Folfox6 second line, the associated
response rate also remained similar to Folfox4, possibly due to oxali-
platin dose modification for haematological toxicity (Maindrault-
Goebel et al, 1999). This led to a redesigned schedule,
FOLFOX7, which increased the dose of oxaliplatin further to
130mgm
 2, but reduced the total number of doses administered
and focused on 5-FU dose reductions in response to non-
neurological toxicity. In a phase II study in relapsed patients,
FOLFOX7 produced a response rate of 42% and grade 3/4
neurological toxicity of 15% (Maindrault-Goebel et al, 2001). A
subsequent study showed that a modified 5-FU schedule combined
with 85mgm
 2 but with reductions of both oxaliplatin and 5-FU
for haematologic toxicity once again reducing the oxaliplatin dose,
was associated with marked reduction in efficacy in the second line
setting – 12% in 37 patients but with a remarkable 72% response
rate in 25 first-line patients (Cheeseman et al, 2002). The
discrepancy remains unexplained, but still suggests that the need
for enhanced dose intensity of oxaliplatin above 85mgm
 2
requires exploration.
In our study, we chose to focus on adjusting the 5-FU ahead of
oxaliplatin and were able to achieve an impressive response rate
and maintain oxaliplatin dose intensity similar to FOLFOX7 (85%
with dose intensity 4100mgm
 2 in first four cycles in Folfox7
Maindrault-Goebel et al (2001) vs 93% in ours), but without
needing to increase the oxaliplatin dose further above 100mgm
 2.
A potential benefit of our schedule lies in the issue of
neurotoxicity.
Oxaliplatin-induced neurotoxicity consists of an acute rapid-
onset sensory neuropathy, often triggered by cold or sudden
temperature changes, and a chronic cumulative sensory neuro-
pathy that occurs after several cycles of treatment, and is
potentially dose limiting. In De Gramont’s et al (2000) phase III
study, 18% of patients experienced grade 3 sensory neurotoxicity;
however, 74% of patients experienced a reversal of neurotoxicity
after treatment was discontinued. In our study, 21% of patients
experienced grade 3 neurotoxicity but with only a limited residual
effect, as at 12 months 71% of patients had recovered. In the
randomised FOLFOX6 study, 34% had grade 3 toxicity. Similarly,
in the recent MOSAIC study (Andre ´ et al, 2004), grade 3
neurotoxicity was observed in 12% of patients, with 94% of
patients experiencing a partial or total recovery within 6 months of
stopping treatment. This is summarised in Table 5. Since the data
suggest that cumulative dose, rather than dose intensity, leads to
neurotoxicity, it follows that patients in our study would be
allowed an increased number of treatment cycles compared with
FOLFOX7.
An alternative approach to dealing with neurotoxicity is
currently being tested by the French group in the Optimox studies
(De Gramont et al, 2004), with previously untreated patients being
randomised to FOLFOX4 until progression, or FOLFOX7 given for
six cycles followed by a simplified LV5FU2 schedule every 2 weeks
for 12 cycles. FOLFOX7 is then reintroduced for six cycles, or
earlier in case of progression, in patients who have a response or
SD at the first FOLFOX administration. From the preliminary
results in 623 patients, the authors have concluded that the
FOLFOX7 arm has a response rate and toxicity similar to the
FOLFOX4 regimen and is more convenient. Only further follow-up
will establish the role of shorter more intensive regimens vs the
established FOLFOX approach. An intermediate regimen that
maximises oxaliplatin dose intensity by focusing on 5-FU dose
modification and preserving oxaliplatin dose may be equally valid.
The recent MOSAIC data (Andre ´ et al, 2004) suggest that
FOLFOX4 has a major role to play in the adjuvant setting, where
enhanced efficacy with increased oxaliplatin dose intensity and
improved convenience are even more important issues. The recent
use of capecitabine combined with oxaliplatin improves conve-
nience and has shown promising efficacy and tolerability data
(Cassidy et al, 2004). This has led to a current randomised trial to
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FOLFOX4, if it is, then attempts to increase oxaliplatin dose
intensity in conjunction with capecitabine may be indicated. In the
interim, this intermediate modification, with a higher dose of
oxaliplatin and an entirely outpatient regimen, appears active,
convenient and safe. Our focus on avoiding oxaliplatin dose
reductions for haematological toxicity increased oxaliplatin dose
intensity, and possibly improved efficacy, without unacceptable
neurologic outcomes. As such, it may be recommended for use in
the metastatic setting to enhance patient acceptability of this
highly active treatment approach while awaiting evidence to
support the routine use of capecitabine and the addition of
targeted therapies such as bevacucimab and cetuximab.
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Table 5 Correlation of oxaliplatin dose and dose intensity with outcomes (progression free survival and response rate) and toxicity
Regimen (ref.)
Regimen
no.
PFS
mos
Planned dose
mgm
 2
Received dose
intensity
Haematologic
toxicity
Grade 3/4 (%)
Neuro Tox.
Grade 3 (%)
Resp. rate
(%)
Folfox N¼46 (Maindrault-Goebelt et al, 2000) 2 7 100 0.98 39 33 46
*
Folfox N¼40 (Maindrault-Goebelt et al, 2000) 3 6 85 0.79 15 28 20
*
Folfox N¼57 (Andre et al, 2003) 4 5.1 85 0.89 37 16 24
*
Folfox N¼210 (De Gramont et al, 2000) 4 9.0 85 0.86 42 18 49
*
Folfox N¼60 (Maindrault-Goebelt et al, 2000) 6 5.3 100 0.86 24 16 27
*
Folfox N¼111 (Tournigand et al, 2004) 6 8.0 100 0.85 44 34 54
*
Folfox N¼48 (Maindrault-Goebelt et al, 2000) 7 130 0.85 9 27 42
*
Cheeseman N¼25 (Cheeseman et al, 2002) 10.6 85 NS 4 0
w 72
*
Goldstein N¼61 8.2 100 0.83 36 21 51
*
*¼Second line Therapy;
w¼Only assessed for first six cycles so not comparable.
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